NASDAQ$RIGL
Rigel Pharmaceuticals Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Rigel reported financial results for the second quarter ended June 30, 2022, featuring the highest quarterly net product sales for TAVALISSE in ITP since launch and strategic expansion with olutasidenib.
Rigel Pharmaceuticals reported a net loss of $13.5 million for Q2 2022, with total revenues of $29.8 million. TAVALISSE net product sales increased by 9% to $18.6 million, and contract revenues from collaborations totaled $11.3 million.
- Highest quarterly net product sales for TAVALISSE in ITP since launch were achieved.
- Strategic expansion of hematology-oncology portfolio to include olutasidenib was completed.
- Total revenues were $29.8 million, comprised of $18.6 million in TAVALISSE net product sales and $11.3 million in contract revenues from collaborations.
- Net loss was $13.5 million, or $0.08 per basic and diluted share.
Headline financials
Revenue & EPS history
Rigel · Revenue · Quarterly
$29.8M
Revenue by segment
Rigel · $11.3M total across 1 segment · Q2 2022
- Collaboration Revenue$11.3M+205.4%100.0%
Forward guidance
Rigel is well-positioned to continue driving momentum for TAVALISSE in ITP and prepare for the potential launch of olutasidenib in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+0.2%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+2.8%
Avg return
30 days after
38%
25 / 65 earnings
Positive
+46.4%
Q3 2024
Best reaction
-18.7%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.8% | -11.8% | +2.3% | |
| Q4 2025 | -10.2% | -15.0% | -16.6% | |
| Q3 2025 | -2.6% | +10.6% | +35.4% | |
| Q1 2025 | +0.9% | +1.9% | +17.7% | |
| Q4 2024 | -8.1% | -11.5% | -21.9% | |
| Q3 2024 | +46.4% | +80.5% | +68.8% | |
| Q2 2024 | +12.2% | +16.0% | +52.4% | |
| Q1 2024 | -18.7% | -19.7% | -21.3% | |
| Q4 2023 | +6.1% | +6.8% | -12.2% | |
| Q3 2023 | +5.8% | -2.4% | +35.7% | |
| Q2 2023 | -6.5% | -11.6% | -17.4% | |
| Q1 2023 | -3.4% | -0.8% | +17.6% | |
| Q4 2022 | +17.8% | +4.6% | -17.8% | |
| Q3 2022 | +5.3% | +4.3% | +18.6% | |
| Q2 2022 | +16.5% | +25.6% | +27.3% | |
| Q1 2022 | +7.3% | -9.8% | -32.5% | |
| Q4 2021 | +21.1% | +21.1% | +19.1% | |
| Q3 2021 | -1.7% | -8.8% | -26.3% | |
| Q2 2021 | -7.2% | -5.2% | +3.2% | |
| Q1 2021 | -5.2% | -7.8% | +15.7% | |
| Q4 2020 | -14.3% | -14.1% | -23.3% | |
| Q3 2020 | -3.0% | +1.5% | +14.1% | |
| Q2 2020 | +3.7% | +6.2% | -4.5% | |
| Q1 2020 | -2.2% | -2.7% | +2.2% | |
| Q4 2019 | -2.3% | +0.5% | -27.6% | |
| Q3 2019 | -1.9% | +4.7% | -5.1% | |
| Q2 2019 | +8.1% | +1.9% | -15.7% | |
| Q1 2019 | -5.5% | -6.7% | -14.7% | |
| Q4 2018 | -0.9% | -1.8% | +13.7% | |
| Q3 2018 | +7.2% | -2.7% | -3.8% | |
| Q2 2018 | +10.2% | +1.1% | +16.8% | |
| Q1 2018 | +5.3% | +7.2% | -10.0% | |
| Q4 2017 | +13.5% | +14.5% | -18.1% | |
| Q3 2017 | +1.1% | +1.6% | +2.4% | |
| Q2 2017 | -1.3% | +1.7% | +7.6% | |
| Q1 2017 | -9.9% | -9.2% | -19.1% | |
| Q4 2016 | +2.6% | +0.8% | +14.3% | |
| Q3 2016 | -3.1% | +1.5% | -3.5% | |
| Q2 2016 | +14.3% | +22.7% | +37.5% | |
| Q1 2016 | -10.9% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q3 2015 | +8.9% | — | — | |
| Q2 2015 | +4.6% | — | — | |
| Q1 2015 | -10.5% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | -10.6% | — | — | |
| Q4 2013 | +17.5% | — | — | |
| Q3 2013 | -9.3% | — | — | |
| Q2 2013 | +2.8% | — | — | |
| Q1 2013 | -0.6% | — | — | |
| Q4 2012 | +5.5% | — | — | |
| Q3 2012 | +2.7% | — | — | |
| Q2 2012 | -7.1% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q4 2009 | -9.0% | — | — | |
| Q4 2011 | -9.0% | — | — | |
| Q3 2010 | -5.9% | — | — | |
| Q3 2011 | -5.9% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q4 2010 | -3.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q1 2011 | -11.5% | — | — | |
| Q1 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro